Can-Fite BioPharma American Depositary Shares
CANF
11 hedge funds and large institutions have $1.62M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
821% more capital inflows, than outflows
Capital inflows: $401K | Capital outflows: $43.6K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
38% more funds holding
Funds holding: 8 → 11 (+3)
4.68% more ownership
Funds ownership: 7.9% → 12.58% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$322K |
| 2 |
Morgan Stanley
New York
|
+$28.4K |
| 3 |
HRT Financial
New York
|
+$25.5K |
| 4 |
Virtu Financial
New York
|
+$24.6K |
| 5 |
Activest Wealth Management
Aventure,
Florida
|
+$473 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31.5K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$7.28K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.82K |
CANF Hedge Fund Activity: Q2 2024 in Review
11 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2024, worth a combined $1.62M — up 53% from $1.06M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $322K. The largest seller was Citadel Advisors, exiting entirely with an estimated $31.5K sold.
- 11 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2024, up from 8 in Q1 2024.
- Funds reported $1.62M of Can-Fite BioPharma American Depositary Shares stock for Q2 2024, up 53% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2024 and 2 closed out, a net change of +3 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2024 was Armistice Capital, an estimated $322K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2024 was Citadel Advisors, an estimated $31.5K sold.
Based on aggregated 13F filings for Q2 2024.